

[Demo] Video on Demand Event



**VIDEO**

**WEB** [www.novartis.com/japan](#)

[www.novartis.com/japan](#)

Tel [0952-97-9167](tel:0952-97-9167)

Web [www.novartis.com/japan](#)

---[www.novartis.com/japan](#)---

[www.novartis.com/japan](#)

[www.novartis.com/japan](#) 9:00 18:00 日・月・火曜日

**We are Novartis,  
and we are  
reimagining  
medicine.**

**VIDEO**

Image



SKIN CLEARANCE is meant by: 69% Psoriasis Area and Severity Index (PASI) 100, an exploratory endpoint, achieved in PsO patients receiving Cosentyx 300 mg (n=80) vs 22.4% of patients receiving narrowband ultraviolet B (nb-UVB) phototherapy (n=80) ( $p < 0.0001$ ) through Week 52. The primary endpoint of PASI 90 response at week 52 for Cosentyx 300 mg vs nb-UVB was met (91.1% vs 42.3% respectively,  $p < 0.0001$ ).

FURTHER is meant by: 90% of PsO patients with PsA (n=191) taking Cosentyx 300 mg showed no radiographic progression through Year 2 (observational data, no statistical testing). The primary endpoint of proportion of patients achieving ACR20 response at Week 16 was met (Cosentyx 300 mg 62.6% vs placebo 27.4%,  $p < 0.0001$ ).

---

**Source URL:** <https://www.pro.novartis.com/be-en/demo-video-demand-event>